| Description | FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola, Rift Valley, and Dengue Fever, with half-maximal effective concentrations (EC50s) of 100 nM, 800 nM, and 400-900 nM, respectively. Additionally, it effectively inhibits non-hemorrhagic fever viruses, notably HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively, indicating its broad-spectrum antiviral potential. |
| In vitro | 在细胞水平的实验中，使用FGI-106处理能够抑制包括正链和负链RNA病毒在内的多种病毒家族的复制。2 μM的FGI-106处理能够相对于对照组使传染性病毒滴度降低4个数量级，其对病毒杀伤宿主细胞（Vero E6细胞）的抑制半最大有效浓度（EC90）估计为0.6 μM。 |
| In vivo | FGI-106 以剂量依赖的方式降低了来自扎伊尔EBOV的死亡率。 |
| Target activity | Rift Valley virus: 800 nM , HCV: 200 nM , HIV-1:150 nM , DENV: 400-900 nM , EBOV:（EC50）100 nM |
| molecular weight | 604.48 |
| Molecular formula | C28H42Cl4N6 |
| CAS | 1149348-10-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 7.5 mg/ml (12.41 mM), Sonication is recommended. |
| References | 1. Aman MJ, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009 Sep;83(3):245-51. |